Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma

CONCLUSION: Apparent survival benefit of extended adjuvant TMZ in newly diagnosed GBM is largely driven by nonrandomized comparative studies with high inherent potential for multiple biases.PMID:37638346 | PMC:PMC10457033 | DOI:10.1093/noajnl/vdad086

Source: Adv Data - August 28, 2023 Category: Epidemiology Authors: Tejpal Gupta Jeevi Mona Priyadharshni Selvarajan Sadhana Kannan Nandini Menon Archya Dasgupta Abhishek Chatterjee Source Type: research